WHO WE ARE
CONSORTIUM LEADERSHIP
WHO WE ARE?
Kevin Winthrop, MD, MPH
Kevin L. Winthrop is a Professor of Public Health at the Oregon Health & Science University-Portland State University School of Public Health (OHSU-PSU SPH), and a Professor of Infectious Diseases and Ophthalmology at the School of Medicine at Oregon Health & Science University in Portland, OR, USA. Dr. Winthrop received his undergraduate degree in biology from Yale University, New Haven, CT, USA and his MD from OHSU. He completed his internal medicine residency training at Legacy Emanuel Hospital, Portland, OR. He completed an infectious disease epidemiology fellowship at the US Centers for Disease Control and Prevention.
In 2003, Dr. Winthrop was conferred a Master in Public Health from the University of California, Berkley, CA, USA. In 2006, Dr. Winthrop returned to OHSU as Assistant Professor before progressing to his current appointment in 2018. A former infectious disease epidemiologist in the Division of Tuberculosis Elimination at the US Centers for Disease Control and Prevention (CDC), Dr. Winthrop has co-authored over 400 publications, many regarding the epidemiologic and clinical aspects of opportunistic infections associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies.
As a primary or senior investigator in many clinical or epidemiologic studies in these fields, he has collaborated closely with the rheumatology community in the evaluation and prevention of opportunistic infections in that setting. In addition, he is also member of the graduate faculty at OHSU where he mentors public health students, medical students, and physicians in post-graduate training. At OHSU, he directs a national referral center for chronic chest infections, and he serves as the medical consultant to the State of Oregon’s Tuberculosis control program.
Ken Oliver, MD, MPH
Dr. Olivier’s main clinical and research focus is on bronchiectasis and chronic airway infections, particularly those caused by the environmental nontuberculous mycobacteria (NTM). His research interests include the population distribution and characteristics of disease, host susceptibility and pathogenesis, and management optimization for chronic pulmonary NTM infections. Dr Olivier’s work on host pathogenesis has identified overlap between idiopathic bronchiectasis patients with NTM infections and gene variants associated with genetic disorders of mucociliary clearance (cystic fibrosis and primary ciliary dyskinesia), heritable connective tissue disorders (e.g. Marfan, Ehlers-Danlos syndromes) and primary immune deficiencies. He is an investigator in the NIH-funded Genetic Disorders of Mucociliary Clearance Consortium with a focus on primary ciliary dyskinesia and other causes of suppurative respiratory tract disease. Therapeutic development interests include both a bench focus on Mycobacterium abscessus preclinical model development, virulence and therapeutic targets and clinical trial optimization for novel antimicrobial therapeutics.
Dr. Oliver received his undergraduate degree from Louisiana State University, and his MD from Tulane University School of Medicine. He completed his residency training at Keesler USAF Medical Center. Additionally, Dr. Oliver completed his fellowship and MPH at the University of North Carolina at Chapel Hill.
Ted Marras, MD, MSC
Dr. Marras is the Director of the Toronto Western Hospital Nontuberculous Mycobacterial Disease Program, a consultant in Respirology at the University Health Network, Toronto, and an Associate Professor of Medicine at the University of Toronto, Canada.
He received his M.D. at Queen’s University (Kingston, Canada), clinical training in Internal Medicine and Respirology at University of Toronto, and M.Sc. (Clinical Epidemiology) at University of Toronto. He completed a mycobacterial diseases fellowship at University of California, San Francisco.
His clinical and research interests are in the field of nontuberculous mycobacterial disease. He is a co-author of the American Thoracic Society, Infectious Diseases Society of America, European Respiratory Society, European Society of Clinical Microbiology and Infectious Disease NTM treatment guidelines.
Chuck Daley, MD
Charles L. Daley, M.D., is Chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health (NJH) and Professor of Medicine at NJH, the University of Colorado School of Medicine, and Icahn School of Medicine at Mount Sinai. He serves as the Chief Research Officer for the Bronchiectasis and NTM Association. Dr. Daley has served on and chaired expert panels for the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America and American Thoracic Society. He chaired the multi-society sponsored revision of the guidelines for the treatment of pulmonary nontuberculous mycobacterial infections. For his work with global MDR-TB control he was awarded the World Lung Health Award by the American Thoracic Society. He was previously Associate Editor of the American Journal of Respiratory and Critical Care Medicine and The European Respiratory Journal and is now Associate Editor for Frontiers in Tuberculosis. His academic interests include clinical and translational research related to TB, NTM and bronchiectasis.
David Grifith, MD
Dr Griffith is currently Professor of Medicine at National Jewish Health (NJH) in Denver Colorado. Prior to joining NJH, he worked for 34 years at UT Health, Tyler, TX where he retired as Professor of Medicine in 2019. He held the William A. and Elizabeth B. Moncrief Distinguished Professorship for 17 years at UT Health. He is an Overseas Fellow of the Royal Society of Medicine and Fellow of the American Thoracic Society and American College of Chest Physicians.
Dr. Griffith was Chief of Tuberculosis Services at UT Health for 15 years. He was Medical Director for the Center for Pulmonary Infectious Disease (CPIDC) at UT Health, which provided free TB consultations for the State of Texas, for 17 years. He was the Assistant Medical Director for the Heartland National TB Center is San Antonio, Texas for 12 years and Medical Director for the Texas State Inpatient TB facility, the Texas Center for Infectious Disease (TCID) for 19 years.
Dr Griffith was a member of the writing committee for the American Thoracic Society (ATS) 1997 Guidelines for Diagnosis and Treatment of Nontuberculous Mycobacteria (NTM) and the chair of the writing committee for the ATS and Infectious Diseases Society of America (IDSA) 2007 Guidelines for Diagnosis, Treatment, and Prevention of NTM) Diseases. He was a member of the international multi-society committee that revised the NTM guidelines in 2020. He also serves as a member of the board of directors of the NTM Information and Research Foundation. Dr Griffith has authored or co-authored more than 300 manuscripts, reviews and book chapters primarily related to NTM disease. He edited a book dedicated to the diagnosis and treatment of NTM infections.
Dr. Griffith was an original member of the NTM Research Consortium 12 years ago and remains an active member.